Rankings
▼
Calendar
SUPN FY 2017 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
SUPN
Supernus Pharmaceuticals, Inc.
$3B
FY 2017 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$302M
+40.6% YoY
Gross Profit
$287M
95.0% margin
Operating Income
$100M
32.9% margin
Net Income
$57M
19.0% margin
EPS (Diluted)
$1.08
Cash Flow
Operating Cash Flow
$115M
Free Cash Flow
$113M
Stock-Based Comp.
$8M
Balance Sheet
Total Assets
$424M
Total Liabilities
$157M
Stockholders' Equity
$267M
Cash & Equivalents
$100M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$302M
$215M
+40.6%
Gross Profit
$287M
$203M
+41.4%
Operating Income
$100M
$54M
+83.6%
Net Income
$57M
$91M
-37.2%
← Q4 2016
All Quarters
Q1 2017 →